Lupin Limited
LIC increased its stake in Lupin Limited from 2.79% to 4.09%, acquiring 5,953,734 additional shares for ₹1,437.08 crore at ₹2406.90 apiece.
An innovation-led pharmaceutical company headquartered in Mumbai, Lupin develops and commercializes a broad range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The company operates as a transnational enterprise, serving customers across more than 100 markets including the United States, India, South Africa, Asia Pacific, Latin America, Europe, and the Middle East regions.
India's largest domestic institutional investor with over Rs 56 lakh crore in total AUM, of which roughly Rs 15 lakh crore sits in listed equities. Holds stakes in virtually every major listed Indian company. When LIC builds or exits a position, it moves markets. Government-owned and mandated to invest policyholder funds in Indian equities and bonds, making it the ultimate long-only, long-term India bull.